Search results
Results from the WOW.Com Content Network
He was key in JP Morgan's development of credit derivatives markets. [ 5 ] [ 6 ] He was appointed co-head of JP Morgan's investment bank along with Steve Black in 2004; Winters was based in London while Black's office was in New York City.
[12] On 26 February 2015, it was announced that his successor would be Bill Winters, former co-CEO of JP Morgan's investment banking business. [ 13 ] After leaving Standard Chartered, Sands was a senior fellow at the Mossavar-Rahmani Center for Business and Government of the Harvard John F. Kennedy School of Government and became the lead non ...
It was chaired by John Vickers [1] and included four other commissioners; Bill Winters, Martin Taylor, Clare Spottiswoode and Martin Wolf.The commissioners were supported by a Secretariat of fourteen officials seconded from HM Treasury, the Department for Business, Innovation and Skills, the Financial Services Authority, the Bank of England and the Office of Fair Trading.
From 1857 through 1871, J.P. Morgan worked his way up through the industry, first as a representative of his father's London-based firm, then as an independent agent for that firm under a self ...
In 2020 Mark Carney established a taskforce for scaling the voluntary carbon markets, chaired by Bill Winters with Nazareth as the operations lead. After a public consultation process, the group released its first report [ 10 ] at Davos 2021 [ 11 ] that recommended [ 12 ] the establishment of an umbrella governance body to improve the ...
Produced by Rodgers, Alex Schmider, Carrie Radigan, Lela Meadow-Conner, and Matthew C. Mills, the documentary boasts cinematography by Bill Winters and Bradley Garrison, who also serves as co ...
As Chairman and CEO of Chase, he and Douglas A. Warner III, then CEO of J.P. Morgan & Co., were the principal architects of the US$30.9 billion acquisition by Chase of J.P. Morgan & Co. in 2000, to form JPMorgan Chase & Co. [1] Harrison has been a director of the Firm or a predecessor institution since 1991. Harrison is also a director of Merck ...
On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the consensus loss of 36 cents. The gene therapy ...